Wealth Enhancement Advisory Services
SANA icon

Wealth Enhancement Advisory Services’s Sana Biotechnology SANA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Sell
61,827
-209
-0.3% -$673 ﹤0.01% 3430
2026
Q1 		$199K Buy
62,036
+8,965
+17% +$35.3K ﹤0.01% 3138
2025
Q4 		$231K Buy
53,071
+199
+0.4% +$891 ﹤0.01% 3152
2025
Q3 		$218K Buy
52,872
+2,023
+4% +$7.31K ﹤0.01% 3063
2025
Q2 		$162K Buy
50,849
+20,585
+68% +$42.5K ﹤0.01% 3041
2025
Q1 		$50.8K Buy
+30,264
New +$84.6K ﹤0.01% 2845

Other funds holding SANA

PAM
Prodigy Asset Management Omaha, Nebraska $332M AUM 10.57% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
BCA
Bay Colony Advisors Concord, Massachusetts $903M AUM 33.67% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Wealth Enhancement Advisory Services's SANA Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Sana Biotechnology (SANA) stake by 0.34% in Q2 2026, selling an estimated $673 and leaving 61,827 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #3430.

Wealth Enhancement Advisory Services first reported a position in SANA in Q1 2025 and has held it in 6 quarters since. 6 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • Wealth Enhancement Advisory Services held 61,827 shares of Sana Biotechnology worth $238K as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 209 Sana Biotechnology shares in Q2 2026, an estimated $673.
  • Sana Biotechnology made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3430 holding.
  • Wealth Enhancement Advisory Services first reported a position in Sana Biotechnology in Q1 2025 and has held it in 6 quarters since.
  • 6 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.